CML

News

Ponatinib back on the market

Ariad Pharmaceuticals, Inc., has begun shipping the drug to Biologics, Inc., its exclusive specialty pharmacy.

News

FDA approves 3rd-generation TKI for CML

Bosutinib is intended for use in patients with chronic, accelerated, or blast phase Philadelphia chromosome-positive CML who have failed therapy...

Pages